press release – price-sensitive

SALES AS OF SEPTEMBER 30, 2024 AMOUNTS TO APPROXIMATELY 2.8 MILLION EUROS

GRANTING OF CONCESSIONS

THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2024

JOINT VENTURE AGREEMENT SIGNED WITH EXOSOMICS S.P.A. FOR THE ESTABLISHMENT OF LONGEVITY BIOSCIENCE SRL

TURNOVER FOR THE FIRST HALF OF 2024 EQUAL TO 2.3 MILLION EUROS, AN INCREASE COMPARED TO THE SAME PERIOD IN 2023

SUBSTANTIAL CHANGE IN MATTER OF OWNERSHIP STRUCTURE

SUBSTANTIAL CHANGE IN MATTER OF OWNERSHIP STRUCTURE

TURNOVER AS OF 31 MARCH 2024 EQUAL TO 1.1 MILLION EUROS, AN INCREASE OF 26.3% COMPARED TO THE SAME PERIOD IN 2023

ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.

SECOND CALL OF SHAREHOLDERS’ MEETING